ARCH Venture Partners announces two new biotech venture funds

Good news for those in the life science sector. ARCH Venture Partners has announced two new venture capital funds that will invest in early stage biotech companies.

Collectively, ARCH Venture Fund X and ARCH Venture Fund X Overage will have $1.46 billion available with the latter fund positioned to take bigger stakes in later stage companies that need more capital. Learn more here.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to Include the name and contact information (phone and email) for follow-up.